Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRAIN: Osimertinib + Anlotinib in EGFR T790M NSCLC
NCT04438902Phase 2Terminated
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- Dec 2020
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of anlotinib in non-small cell lung cancer (NSCLC), sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Started Dec 2020; status: terminated.
02
Drugs
anlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04438902.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04438902.